Is Mereo BioPharma Group plc - ADR (MREO) Stock About to Get Hot Wednesday?

Mereo BioPharma Group plc - ADR (MREO) stock is up 15.12% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Mereo BioPharma Group plc - ADR has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on MREO!

See Full MREO Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With MREO Stock Today?

Mereo BioPharma Group plc - ADR (MREO) stock is lower by -1.25% while the S&P 500 is up 0.28% as of 1:15 PM on Wednesday, Nov 1. MREO is down -$0.03 from the previous closing price of $2.01 on volume of 281,557 shares. Over the past year the S&P 500 is up 8.61% while MREO is up 98.00%. MREO lost -$0.34 per share in the over the last 12 months. To screen for more stocks like Mereo BioPharma Group plc - ADR click here.

More About Mereo BioPharma Group plc - ADR

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for oncology and rare diseases. Its lead oncology product candidate is etigilimab, for patients with advanced solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod. Click Here to get the full Stock Report for Mereo BioPharma Group plc - ADR stock.